Possible case of quetiapine-induced rhabdomyolysis in a patient with depression treated with fluoxetine [8]

Journal of Clinical Psychopharmacology

Volumn 26, Issue 6, 2006, Pages 676-677

  Himmerich, Hubertus ^a   Ehrlinger, Martin ^b   Hackenberg, Melanie ^c   Löhr, Birgit ^c   Nickel, Thomas ^a  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b Psychiatry/Psychotherapy Practice   (Germany)

^c Klinikum Schwabing   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AMISULPRIDE; ASPARTATE AMINOTRANSFERASE; CREATINE KINASE; FLUOXETINE; QUETIAPINE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL PARAMETERS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMISTRY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DEPRESSION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GALACTORRHEA; HUMAN; LETTER; MUSCLE DISEASE; PRIORITY JOURNAL; PSYCHOTHERAPY; RHABDOMYOLYSIS; TREATMENT REFUSAL;

ADULT; ALANINE TRANSAMINASE; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; ASPARTATE AMINOTRANSFERASES; CREATINE KINASE; DEPRESSION; DIBENZOTHIAZEPINES; DRUG THERAPY, COMBINATION; FEMALE; FLUOXETINE; HUMANS; RHABDOMYOLYSIS;

EID: 33751089818     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000245560.21907.a4     Document Type: Letter

References (13)

1. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 1996;15:395-405.
2. Smith RP, Puckett BN, Crawford J, et al. Quetiapine overdose and severe rhabdomyolysis. J Clin Psychopharmacol. 2004;24:343.
3. Karch FE, Lasagna L. Adverse drug reactions. A critical review. JAMA. 1975;234:1236-1241.
4. Naranjo CA, Shear NH, Lanctot KL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32:897-904.
5. Bilbao Garay J, Mesa Plaza N, Castilla Castellano V, et al. Serotonin syndrome: report of a fatal case and review of the literature. Rev Clin Esp. 2002;202:209-211.
6. Lazarus A. Rhabdomyolysis in a depressed patient following overdose with combined drug therapy and alcohol. J Clin Psychopharmacol. 1990;10:154-155.
7. Spina E, Scordo MG, D'Arrigo C. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517-538.
8. Potkin SG, Thyrum PT, Alva G, et al. Pharmacokinetic Study Group. Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol. 2002;22(2):174-182.
9. Gurrera RJ. Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome. Am J Psychiatry. 1999;156:169-180.
10. Burniston JG, Ellison GM, Clark WA, et al. Relative toxicity of cardiotonic agents: some induce more cardiac and skeletal myocyte apoptosis and necrosis in vivo than others. Cardiovasc Toxicol. 2005;5:355-364.
11. Bloom S. Catecholamine cardiomyopathy. N Engl J Med. 1987;317:900-901.
12. Veith RC, Lewis N, Linares OA, et al. Geriatric Research, Education, and Clinical Center, Seattle, (Wash) VAMC. Sympathetic nervous system activity in major depression. Basal and desipramine-induced alterations in plasma norepinephrine kinetics. Arch Gen Psychiatry. 1994;51:411-422.
13. Knochel JP. Mechanisms of rhabdomyolysis. Curr Opin Rheumatol. 1993;5:725-731.